➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Express Scripts
Johnson and Johnson
Colorcon
Merck

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 9,555,022

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,555,022
Title:Substituted triazolopyridines
Abstract: The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease of uncontrolled cell growth, proliferation and/or survival as well as to the use of intermediate compounds for the preparation of said compounds. ##STR00001##
Inventor(s): Schulze; Volker (OT Bergfelde, DE), Kosemund; Dirk (Berlin, DE), Schirok; Hartmut (Langenfeld, DE), Bader; Benjamin (Berlin, DE), Lienau; Philip (Berlin, DE), Wengner; Antje Margret (Berlin, DE), Briem; Hans (Berlin, DE), Holton; Simon (Berlin, DE), Siemeister; Gerhard (Berlin, DE), Prechtl; Stefan (Berlin, DE), Koppitz; Marcus (Berlin, DE), Stockigt; Detlef (Potsdam, DE), Prien; Olaf (Berlin, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:13/704,859
Patent Claims:see list of patent claims

Details for Patent 9,555,022

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Bayer Intellectual Property GmbH (Monheim, DE) 2030-06-16 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Bayer Intellectual Property GmbH (Monheim, DE) 2030-06-16 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Bayer Intellectual Property GmbH (Monheim, DE) 2030-06-16 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Bayer Intellectual Property GmbH (Monheim, DE) 2030-06-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
McKinsey
Moodys
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.